These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16249389)

  • 21. Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells.
    Seth S; Qiu Q; Danisch S; Maier MK; Braun A; Ravens I; Czeloth N; Hyde R; Dittrich-Breiholz O; Förster R; Bernhardt G
    J Biol Chem; 2011 Nov; 286(45):39153-63. PubMed ID: 21937446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNAM-1 and PVR regulate monocyte migration through endothelial junctions.
    Reymond N; Imbert AM; Devilard E; Fabre S; Chabannon C; Xerri L; Farnarier C; Cantoni C; Bottino C; Moretta A; Dubreuil P; Lopez M
    J Exp Med; 2004 May; 199(10):1331-41. PubMed ID: 15136589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction.
    Ardolino M; Zingoni A; Cerboni C; Cecere F; Soriani A; Iannitto ML; Santoni A
    Blood; 2011 May; 117(18):4778-86. PubMed ID: 21406724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
    Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction.
    Castriconi R; Dondero A; Corrias MV; Lanino E; Pende D; Moretta L; Bottino C; Moretta A
    Cancer Res; 2004 Dec; 64(24):9180-4. PubMed ID: 15604290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNAM-1 controls NK cell activation via an ITT-like motif.
    Zhang Z; Wu N; Lu Y; Davidson D; Colonna M; Veillette A
    J Exp Med; 2015 Nov; 212(12):2165-82. PubMed ID: 26552706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors.
    Gilfillan S; Chan CJ; Cella M; Haynes NM; Rapaport AS; Boles KS; Andrews DM; Smyth MJ; Colonna M
    J Exp Med; 2008 Dec; 205(13):2965-73. PubMed ID: 19029380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.
    Toutirais O; Cabillic F; Le Friec G; Salot S; Loyer P; Le Gallo M; Desille M; de La Pintière CT; Daniel P; Bouet F; Catros V
    Eur J Immunol; 2009 May; 39(5):1361-8. PubMed ID: 19404979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.
    Tahara S; Okumura G; Matsuo T; Shibuya A; Shibuya K
    Int Immunol; 2024 Apr; 36(6):317-325. PubMed ID: 38289706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.
    Ott M; Avendaño-Guzmán E; Ullrich E; Dreyer C; Strauss J; Harden M; Schön M; Schön MP; Bernhardt G; Stadelmann C; Wegner C; Brück W; Nessler S
    J Neuroinflammation; 2019 Feb; 16(1):49. PubMed ID: 30808363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells.
    Davis ZB; Sowrirajan B; Cogswell A; Ward JP; Planelles V; Barker E
    AIDS Res Hum Retroviruses; 2017 Feb; 33(2):93-100. PubMed ID: 27296670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD155/CD226-interaction impacts on the generation of innate CD8(+) thymocytes by regulating iNKT-cell differentiation.
    Georgiev H; Ravens I; Shibuya A; Förster R; Bernhardt G
    Eur J Immunol; 2016 Apr; 46(4):993-1003. PubMed ID: 26689152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8
    Braun M; Aguilera AR; Sundarrajan A; Corvino D; Stannard K; Krumeich S; Das I; Lima LG; Meza Guzman LG; Li K; Li R; Salim N; Jorge MV; Ham S; Kelly G; Vari F; Lepletier A; Raghavendra A; Pearson S; Madore J; Jacquelin S; Effern M; Quine B; Koufariotis LT; Casey M; Nakamura K; Seo EY; Hölzel M; Geyer M; Kristiansen G; Taheri T; Ahern E; Hughes BGM; Wilmott JS; Long GV; Scolyer RA; Batstone MD; Landsberg J; Dietrich D; Pop OT; Flatz L; Dougall WC; Veillette A; Nicholson SE; Möller A; Johnston RJ; Martinet L; Smyth MJ; Bald T
    Immunity; 2020 Oct; 53(4):805-823.e15. PubMed ID: 33053330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
    Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
    Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo.
    Cerwenka A; Baron JL; Lanier LL
    Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11521-6. PubMed ID: 11562472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway.
    Westwood JA; Kelly JM; Tanner JE; Kershaw MH; Smyth MJ; Hayakawa Y
    J Immunol; 2004 Jan; 172(2):757-61. PubMed ID: 14707044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNAM-1: an amplifier of immune responses as a therapeutic target in various disorders.
    Elishmereni M; Bachelet I; Levi-Schaffer F
    Curr Opin Investig Drugs; 2008 May; 9(5):491-6. PubMed ID: 18465659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNAM-1 promotes inflammation-driven tumor development via enhancing IFN-γ production.
    Nakamura-Shinya Y; Iguchi-Manaka A; Murata R; Sato K; Vo AV; Kanemaru K; Shibuya A; Shibuya K
    Int Immunol; 2022 Feb; 34(3):149-157. PubMed ID: 34672321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins.
    de Andrade LF; Smyth MJ; Martinet L
    Immunol Cell Biol; 2014 Mar; 92(3):237-44. PubMed ID: 24343663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1.
    Deuss FA; Watson GM; Goodall KJ; Leece I; Chatterjee S; Fu Z; Thaysen-Andersen M; Andrews DM; Rossjohn J; Berry R
    J Biol Chem; 2019 Aug; 294(33):12534-12546. PubMed ID: 31253644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.